Allarity Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2024
Filed with the SEC on Mar 31, 2025 and accepted by EDGAR at Mar 31, 2025, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2024-01-01 to 2024-12-31 | $6.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$27.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2024-01-01 to 2024-12-31 | $653.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2024-01-01 to 2024-12-31 | −$381.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$24.5m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$15.65 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$17.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $298.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $19.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $22.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $22.6m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $10.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $10.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $11.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-25-010198. Last ingested by Listed: Nov 2, 2026, 08:01 ET. Listed shows no prices and gives no investment advice.